

Supplementary Table 9. Adverse events and mortality according to baseline GAP stage

Variable	GAP I (n = 168)	GAP II–III (n = 159)	p value
Adverse event			
Total	133 (79.2)	134 (84.3)	0.233
Anorexia	50 (29.8)	69 (43.4)	0.010
Skin rash	55 (32.7)	38 (23.9)	0.077
Dyspepsia	41 (24.4)	46 (28.9)	0.355
Nausea	25 (14.9)	38 (23.9)	0.039
General weakness	17 (10.1)	34 (21.4)	0.005
Liver function test abnormality	21 (12.5)	21 (13.2)	0.848
Photosensitivity	19 (11.3)	13 (8.2)	0.341
Fatigue	11 (6.5)	11 (6.9)	0.894
Diarrhoea	9 (5.4)	9 (5.7)	0.904
Others	27 (16.1)	29 (18.2)	0.603
Discontinuation of treatment due to adverse event	37 (22.0)	45 (28.3)	0.191
Overall death	9 (5.4)	26 (16.4)	0.001
IPF-related death	7 (4.2)	23 (14.5)	0.001

Values are presented as number (%).

GAP, Gender-Age-Physiology; IPF, idiopathic pulmonary fibrosis.